Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Martin Reck, Julie R. Brahmer, Delvys Rodríguez‐Abreu et al.|Journal of Clinical Oncology|2021Cited by 1.1k
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 StudySilvia Novello, Luis Paz‐Ares, Dariusz M. Kowalski et al.|Journal of Clinical Oncology|2023Cited by 541
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S. Carlino, Adil Daud, Marta Nyakas et al.|European Journal of Cancer|2018Cited by 98